StemCell Therapy

Despite what many of us might like to believe, COVID-19 has not gone away. South Africa recently identified two new subvariants of Omicron designated BA.4 and BA.5. These subvariants have now spread to several other countries, including the United Kingdom and the United States. Should we be concerned about them? Medical News Today assessed the evidence and spoke to experts in the U.S. and the U.K. to find out.

Alpha, Beta, Gamma, Delta, Omicron the list of SARS-CoV-2 variants continues to expand. And no sooner have we got used to one variant than another appears.

Latest on the list are the Omicron subvariants BA.4 and BA.5, which were identified recently in South Africa, one of the few countries that are still sequencing large numbers of COVID-19 tests.

South Africa has seen a rapid increase in positive tests for COVID-19, and authorities believe that BA.4 and BA.5 are responsible. The National Institute of Clinical Diseases in South Africa reports that BA.4 and BA.5 are Omicron viruses with a new combination of mutations.

Scientists in this country first detected BA.4 on January 10, 2022, and it has since spread throughout South Africa, now making up 35% of positive tests. BA.5 was identified on February 25, and now accounts for 20% of cases in several South African regions.

Both subvariants are similar to Omicron BA.2, which is currently dominant in the U.K., continental Europe, and the U.S.

BA.4 and BA.5 have identical mutations on their spike protein the part of the virus that attaches to receptors on human cells that differentiate them from BA.2. Each subvariant has its own different mutations in other areas of the virus.

We have learned that the [COVID-19-causing variants] are more mutable than we initially thought. Periodically we get major new variants thats a big shift. But we also get little, what we call drift variants. You can think of them as members of the same family [] theyre like cousins.

Prof. William Schaffner, professor of infectious diseases at the Vanderbilt University School of Medicine in Nashville, TN

So far, BA.4 and BA.5 have been identified in several countries in addition to South Africa. According to a report from the U.K. Health Security Agency (UKHSA), with data up to April 22, BA.4 was present in Austria, the U.K., the U.S., Denmark, Belgium, Israel, Germany, Italy, Canada, France, the Netherlands, Australia, Switzerland, and Botswana.

On the same date, health authorities had identified BA.5 in Portugal, Germany, the U.K., the U.S., Denmark, France, Austria, Belgium, Hong Kong, Australia, Canada, Israel, Norway, Pakistan, Spain, and Switzerland.

Few countries are sequencing large numbers of positive tests, despite the Director-General of the World Health Organization (WHO) stating on May 4 that testing and sequencing remain absolutely critical.

In many countries were essentially blind to how the virus is mutating. We dont know whats coming next.

Dr. Tedros Adhanom Ghebreyesus, WHO Director-General

He is not alone in his concern about the lack of sequencing. Prof. Christina Pagel, professor of operational research at University College London (UCL) and director of the UCL Clinical Operational Research Unit, told Medical News Today that [w]e are opening ourselves up to a serious new wave particularly in winter that we would not be able to spot in time.

Although the numbers recorded for both variants are currently low, the actual case numbers are likely to be much higher. Without sequencing of positive tests, the variants that cause COVID-19 cannot be identified.

On May 12, the European Centre for Disease Prevention and Control (ECDC) reclassified BA.4 and BA.5 as variants of concern. This followed a sharp rise in cases in Portugal, where the Portuguese National Institute of Health estimated on May 8 that BA.5 was responsible for around 37% of all positive cases.

The ECDC reports that although there is no evidence yet of increased severity over previous variants, BA.4 and BA.5 do appear to be more transmissible.

The Omicrons are an extraordinarily contagious family. There are some data that say these subvariants are even more contagious. [] Do they have the capacity to produce more severe disease? At the moment, if anything, Omicron seems to be on the milder side.

Prof. William Schaffner

In the U.S., the Centers for Disease Control and Prevention (CDC) have also designated BA.4 and BA.5 as variants of concern.

The U.K. has not yet followed suit. However, the UKHSA published a risk assessment of the two subvariants comparing them with Omicron BA.2. This suggests that the new subvariants may be better at evading the immune system than BA.2, but that the data is insufficient to draw firm conclusions.

In South Africa, which has identified the greatest number of cases, symptoms and severity seem similar to those of disease caused by Omicron BA.2. So far, the number of hospitalizations there has increased only slightly.

Some good news from GAVI the vaccine alliance is that although antibodies from previous Omicron infection do not seem to afford much protection against the new variants, antibodies from vaccination appear to be much more effective.

Prof. Schaffner agreed that vaccines should protect against severe disease from the new variants: These are slightly different mutations of the spike protein are they so different that they cannot be responsive to our vaccines? The answer is no.

However, he is concerned that vaccine fatigue may be having an effect:

Of course, vaccines dont prevent disease vaccination prevents disease. And the issue, at least in [the U.S.], is can we persuade people to come forward yet again to be vaccinated? There is clearly vaccine fatigue out there.

He added that [t]he more people we can vaccinate around the world [the more we can] reduce the chance of these rogue variants popping up.

Prof. Jonathan Stoye, FRS, principal group leader, and international affairs ambassador at the Francis Crick Institute in London, U.K., agreed: It does not seem unreasonable to ask whether a greater emphasis should not be placed on attempting to provide and deliver a vaccine which can be administered to all the worlds unprotected people, particularly those in lower and middle-income countries.

It is likely that BA.4 and BA.5 will spread further, and that they will not be the last new variants.

Prof. Pagel expressed concern that lack of testing and sequencing may mean that variants are not detected early: [I]n England, for instance, we are only really doing PCR tests on hospital admissions [] [and] because admissions are skewed towards older populations, it will take longer for variants to show up if they spread first among children and young people as has been typical so far.

These concerns were echoed by Prof. Schaffner, who said that [w]e require a coordinated international surveillance system, and critical to that is the sequencing of viruses. Number one: To detect these minor subvariants. Its always better to know than not [to] know.

And then, of course, the sequencing is utterly important to pick up that rare event when we would get another rogue strain that could evade the protection of our vaccines, he added.

It is likely that COVID-19, in whatever form, will be with us for some years to come the key question is, can we keep it under control as we try to get life back to normal?

As weve moved from pandemic phase to endemic, how will we cope? Are we going to come to some sort of fraught truce with this virus? We havent figured out how to do that yet.

Prof. William Schaffner

More here:
Omicron BA.4 and BA.5: What to know about the new variants - Medical News Today

PITTSBURGH, May 19, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS), the leader in redosable gene therapy, is pleased to present new data entitled GEM-3: phase 3 safety and immunogenicity results of beremagene geperpavec (B-VEC), an investigational, topical gene therapy for dystrophic epidermolysis bullosa (DEB) at the Society for Investigative Dermatology 2022 Annual Meeting, taking place May 18-21 in Portland, Oregon.

Krystal Presentation

GEM-3: phase 3 safety and immunogenicity results of beremagene geperpavec (B-VEC), an investigational, topical gene therapy for dystrophic epidermolysis bullosa (DEB)M. Peter Marinkovich, MD, FAADPoster Session 1Date & Time: Thursday, May 19, 4:30-6:30pm PDT

ePoster Presentation: Session 2, Genetic Disease, Gene Regulation, and Gene TherapyDate & Time: Friday, May 20, 5:54-6:00pm PDT

The poster and ePoster will be available to conference attendees. To register for the conference, please visit SID 2022 Annual Meeting | Society for Investigative Dermatology. The Company will be present at Booth 218 to educate about DEB and the mechanism of the disease. Following the presentation, materials will be available to view online on the Investor section of the Companys website.

About Dystrophic Epidermolysis Bullosa (DEB)DEB is a rare and severe disease that affects the skin and mucosal tissues. It is caused by one or more mutations in a gene calledCOL7A1, which is responsible for the production of the protein type VII collagen (COL7) that forms anchoring fibrils that bind the dermis (inner layer of the skin) to the epidermis (outer layer of the skin). The lack of functional anchoring fibrils in DEB patients leads to extremely fragile skin that blisters and tears from minor friction or trauma. DEB patients suffer from open wounds, which leads to skin infections, fibrosis which can cause fusion of fingers and toes, and ultimately an increased risk of developing an aggressive form of squamous cell carcinoma which, in severe cases, can be fatal.

About B-VECB-VECis an investigational non-invasive, topical, redosable gene therapy designed to deliver two copies of theCOL7A1gene when applied directly to DEB wounds. B-VEC was designed to treat DEB at the molecular level by providing the patients skin cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism.

TheU.S. Food and Drug Administration(FDA) and theEuropean Medicines Agency(EMA) have each granted B-VEC an orphan drug designation for the treatment of DEB. The FDA has also granted B-VECfast track designation and rare pediatric designation for the treatment of DEB. In addition, in 2019, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) to B-VEC for the treatment of DEB and the EMA granted PRIority MEdicines ("PRIME") eligibility for B-VECto treat DEB.

About Krystal Biotech, Inc.Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to develop life-changing medicines for patients with serious diseases, including rare diseases in skin, lung, and other areas. For more information please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and Twitter.

CONTACTS:Investors and Media:Meg DodgeKrystal Biotechmdodge@krystalbio.com

Source: Krystal Biotech, Inc.

Read the rest here:
Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting -...

Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials

While not indicated for weight loss, Mounjaro led to significantly greater weight reductions versus comparators in a key secondary endpoint

Mounjaro represents the first new class of diabetes medicines introduced in nearly a decade and is expected to be available in the U.S. in the coming weeks

INDIANAPOLIS, May 13, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Mounjaro (tirzepatide) injection, Eli Lilly and Company's (NYSE: LLY) new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Mounjaro has not been studied in patients with a history of pancreatitis and is not indicated for use in patients with type 1 diabetes mellitus.

As the first and only FDA-approved GIP and GLP-1 receptor agonist, Mounjaro is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones.1

"Mounjaro delivered superior and consistent A1C reductions against all of the comparators throughout the SURPASS program, which was designed to assess Mounjaro's efficacy and safety in a broad range of adults with type 2 diabetes who could be treated in clinical practice. The approval of Mounjaro is an exciting step forward for people living with type 2 diabetes given the results seen in these clinical trials," said Juan Pablo Fras, M.D., Medical Director, National Research Institute and Investigator in the SURPASS program.

Mounjaro will be available in six doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) and will come in Lilly's well-established auto-injector pen with a pre-attached, hidden needle that patients do not need to handle or see.

The approval was based on results from the phase 3 SURPASS program, which included active comparators of injectable semaglutide 1 mg, insulin glargine and insulin degludec. Efficacy was evaluated for Mounjaro5 mg, 10 mg and 15 mg used alone or in combination with commonly prescribed diabetes medications, including metformin, SGLT2 inhibitors, sulfonylureas and insulin glargine. Participants in the SURPASS program achieved average A1C reductions between 1.8% and 2.1% for Mounjaro 5 mg and between 1.7% and 2.4% for both Mounjaro 10 mg and Mounjaro 15 mg. While not indicated for weight loss, mean change in body weight was a key secondary endpoint in all SURPASS studies. Participants treated with Mounjaro lost between 12 lb. (5 mg) and 25 lb. (15 mg) on average.1

Side effects reported in at least 5% of patients treated with Mounjaro include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion (dyspepsia), and stomach (abdominal) pain. The labeling for Mounjaro contains a Boxed Warning regarding thyroid C-cell tumors. Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2.1

"Lilly has a nearly 100-year heritage of advancing care for people living with diabetes never settling for current outcomes. We're not satisfied knowing that half of the more than 30 million Americans living with type 2 diabetes are not reaching their target blood glucose levels," said Mike Mason, president, Lilly Diabetes. "We are thrilled to introduce Mounjaro, which represents the first new class of type 2 diabetes medication introduced in almost a decade and embodies our mission to bring innovative new therapies to the diabetes community."

Mounjaro is expected to be available in the United States in the coming weeks. Lilly is committed to helping people access the medicines they are prescribed and will work with insurers, health systems and providers to help enable patient access to Mounjaro. Lilly plans to offer a Mounjaro savings card for people who qualify. Patients or healthcare professionals with questions about Mounjaro can visit http://www.Mounjaro.com or call The Lilly Answers Center at 1-800-LillyRx (1-800-545-5979).

Tirzepatide is also under regulatory review for the treatment of type 2 diabetes in Europe, Japan and several additional markets. A multimedia gallery is available on Lilly.com.

About the SURPASS clinical trial programThe SURPASS phase 3 global clinical development program for tirzepatide began in late 2018 and included five global registration trials and two regional trials in Japan. These studies ranged from 40 to 52 weeks and evaluated the efficacy and safety of Mounjaro 5 mg, 10 mg and 15 mg as a monotherapy and as an add-on to various standard-of-care medications for type 2 diabetes. The active comparators in the studies were injectable semaglutide 1 mg, insulin glargine and insulin degludec. Collectively, the five global registration trials consistently demonstrated A1C reductions for participants taking Mounjaro across multiple stages of their type 2 diabetes journeys, from an average around five to 13 years of having diabetes.2-8

*p<0.001 for superiority vs. placebo or active comparator, adjusted for multiplicityp<0.05 for superiority vs. semaglutide 1 mg, adjusted for multiplicity

About Mounjaro (tirzepatide) injection1Mounjaro (tirzepatide) injection is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. As the first and only FDA-approved GIP and GLP-1 receptor agonist, Mounjaro is a single molecule that activates the body's receptors for GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Mounjaro will be available in six doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) and will come in Lilly's well-established auto-injector pen with a pre-attached, hidden needle that patients do not need to handle or see.

PURPOSE AND SAFETY SUMMARY WITH WARNINGSImportant Facts About MounjaroTM (mown-JAHR-OH). It is also known as tirzepatide.

WarningsMounjaro may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have a symptom, tell your healthcare provider.

Mounjaro may cause serious side effects, including:

Inflammation of the pancreas (pancreatitis). Stop using Mounjaro and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Mounjaro with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, or mood changes, hunger, weakness and feeling jittery.

Serious allergic reactions. Stop using Mounjaro and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, and very rapid heartbeat.

Kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration.

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Mounjaro. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Changes in vision. Tell your healthcare provider if you have changes in vision during treatment with Mounjaro.

Gallbladder problems. Gallbladder problems have happened in some people who use Mounjaro. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), and clay-colored stools.

Common side effectsThe most common side effects of Mounjaro include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach (abdominal) pain. These are not all the possible side effects of Mounjaro. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

Tell your healthcare provider if you have any side effects. You can report side effects at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

Before using

Review these questions with your healthcare provider:

How to take

Learn moreFor more information, call 1-800-LillyRx (1-800-545-5979) or go towww.mounjaro.com.

This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Mounjaro and how to take it. Your healthcare provider is the best person to help you decide if Mounjaro is right for you.

MounjaroTM and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Please click to access full Prescribing Informationand Medication Guide.

TR CON CBS MAY2022

About LillyLilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visitLilly.comandLilly.com/newsroomor follow us onFacebook,Instagram, Twitterand LinkedIn. P-LLY

Lilly Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Mounjaro (tirzepatide 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg) injection as a treatment to improve glycemic control in adults with type 2 diabetes, the timeline for supply of Mounjaro to become available, and certain other milestones and ongoing clinical trials of Mounjaro and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product or medical device, there are substantial risks and uncertainties in the process of research, development and commercialization. Among other things, there can be no guarantee thatMounjarowill be commercially successful,that future study results will be consistent with results to date, or that we will meet our anticipated timelines for the commercialization of Mounjaro. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

References

PP-TR-US-0125 05/2022 Lilly USA, LLC 2022. All rights reserved.

View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-approves-lillys-mounjaro-tirzepatide-injection-the-first-and-only-gip-and-glp-1-receptor-agonist-for-the-treatment-of-adults-with-type-2-diabetes-301547339.html

SOURCE Eli Lilly and Company

The rest is here:
FDA approves Lilly's Mounjaro (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2...

Sitting atop each kidney and measuring only around two centimeters long, the adrenal glands are tiny but mighty. These glands produce steroid hormones, including those involved in stress response, blood pressure maintenance, and fertility. When their development goes awry, it can cause a life-threatening condition called primary adrenal insufficiency, also known as Addisons disease. Many of the genetics involved in this and other adrenal gland disorders remain unknown.

Research on adrenal glands has often relied on insights made using mouse models. Now, a new study led by the School of Veterinary Medicines Kotaro Sasaki, which examined the developmental origin of the glands in humans and nonhuman primates, finds key developmental differences. This new understanding may inform diagnostics and treatment for Addisons disease and other endocrine system disorders.

The work was published in the journal Science Advances.

While some genetic causes of primary adrenal insufficiency have been identified, the mechanism has remained poorly understood, says Sasaki. Our findings help in identifying genes involved in adrenal development and could lead to new targets for therapeutic intervention.

Sasakis investigations have centered around studied gonadal development, how cells become ovaries or testes, organs that, like the adrenal gland, release hormones. Given this background, the adrenal gland was a natural next focus, especially because it has a shared origin with the gonads. In their recent work, Sasaki and colleagues looked at some of the earliest developmental stages to see how precursor cells and tissues evolve to give rise to the adrenal gland.

Scientists have long known that both the gonads and adrenal gland develop from a tissue known as the coelomic epithelium (CE), which is present at an early stage of embryonic development. In mice, for example, this tissue develops into the adrenogonadal primordium, which later divides to form both the adrenal primordium and the gonadal progenitor. The adrenal primodium goes on to become the adrenal gland, and the gonadal progenitor develops into either ovaries or testes.

Using immunofluorescence and in situ hybridization analyses, in which markers enable scientists to track cells descendants, Sasaki and his team found that primate CE expressed different genes than mouse CE. Whereas mice expressed the WT1, GATA4, and NR5A1 genes within the adrenogonadal primordium, primates did not express GATA4 in a parallel stage of development, a surprise to the researchers.

Whats more, while one portion of the primate CE led to the gonadal precursor, the other developed into the adrenal gland precursors, a division that wasnt present in mice.

It takes place in a way thats totally different from the mouse, says Sasaki. It appears that the portion of the coelomic epithelium that gives rise to the gonads is spatially separated from the part that gives rise to the adrenal gland.

Single-cell sequencing further revealed different patterns of gene expression between the adrenal and gonadal cell lineages, as well as a clear divergence between humans and mice. Some of these differentially expressed genes, Sasaki notes, are likely important in the process of deriving adrenal or gonadal tissues from CE.

Certain genes, Sasaki says, could also be examined in the context of adrenal insufficiency.

Currently, people with Addisons disease are treated with a lifelong steroid replacement therapy, using synthetic hormones to substitute for those that their bodies cant make on their own. Its not a cure and comes with serious side effects, Sasaki says.

In future work, he and colleagues hope to lay the groundwork in the lab to generate the adrenal cortex, employing inducible pluripotent stem cells, cells derived from blood or skin that can be induced to become a variety of different cell types. With such an approach, they could coax the stem cells to follow the normal developmental pathway toward becoming adrenal tissue. While in its early stages, this could enable a cell-based therapy for primary adrenal insufficiency, ideally avoiding some of the drawbacks of hormone replacement therapy.

Were pursuing in vitro studies to continue mapping out a blueprint that could be applicable to humans, Sasaki says.

Kotaro Sasaki is an assistant professor in the Department of Biomedical Sciences at the University of Pennsylvania School of Veterinary Medicine.

Sasakis coauthors were Penn Vets Keren Cheng, Yasunari Seita, Taku Moriwaki, Yuka Sakata, and Young Sun Hwang; Kiwamu Noshiro, Hidemichi Watari, and Takeshi Umazume of Hokkaido University; Toshihiko Torigoe of Sapporo Medical University; Mitinori Saitou of Kyoto University; Hideaki Tsuchiya and Chizuru Iwatani of Shiga University of Medical Science; Masayoshi Hosaka of the Fukuzumi Obstetrics and Gynecology Hospital; and Toshihiro Ohkouchi of Ohkouchi Obstetrics and Gynecology Hospital.

Sasaki was corresponding author and Cheng, Seita, and Moriwaki were co-first authors of the work, which was supported in part by the Japanese Science and Technology Agency (grants JPMJCE1301 and JPMJER1104), Silicon Valley Community Foundation, and Good Ventures Foundation.

The rest is here:
Elucidating the developmental origin of life-sustaining adrenal glands | Penn Today - Penn Today

Ive known Brent Rutemiller CEO of Swimming World and the International Swimming Hall of Fame for about 20 years, our relationship first developed through business. But when you work closely with someone, there is a great opportunity to develop a friendship and Im glad that I get to call Brent a good friend. So, when he reached out almost a year ago with the news that he was diagnosed with plasma-cell leukemia, it was a tough conversation to say the least.

Yet, something from our early chats stood out. Brent didnt have this woe-is-me mentality. Truthfully, he didnt have time for that attitude, nor did he care to mope. No, Brent was going to beat this thing. How? Those details would come later, and as you will see in his letter below, his fight was not without several pitfalls, moments of doubt and frustration. Through it all, though, Brent remained positive, refused to dwell on any setbacks and was steadfast in the fact that one day he was going to receive excellent news and could be used as motivation for others battling a cancer diagnosis.

Today, Swimming World is thrilled to announce that Brent is in early remission from the cancer which wracked his body. Its an achievement to celebrate, and as I told Brent last week, this wonderful news is his moment atop the podium. He claimed victory. He beat the opposition. He captured gold.

The following letter is Brent Rutemillers detailed announcement of the early-remission news delivered by his doctor regarding his fight against cancer.

I finally got my long-awaited blood test results to see if my stem cell transplant was successful.

It will soon be one year since I was diagnosed with cancer. 90% of my plasma was filled with cancer and my kidneys were failing over Memorial Day Weekend last year. Dr. Google said I had 5 months to live. The first 48 hours, I felt sorry for myself. Then I decided that feeling sorry was a useless emotion. I was going to either win or die, there was no second place. I made the decision that the only thing I can control was my attitude and exercise.

I began walking circles in my hospital room and then progressed to the hospital floor. They put a port in my chest and started giving me chemo three times a week. They flooded me with pills to the point that on some days I was taking over 20 within a 24-hour period. They pounded me with steroids once a week to where I now have cataracts in both eyes and will need surgery.

Photo Courtesy:

With the help of Rob Butcher, I was able to get Dr. Fonseca, head of the Mayo Oncology Department to take me as his patient, but first Mayo had to accept me into their system. With the constant loving support of my wife, Ellen Rutemiller, she navigated the insurance paperwork and maze of hoops to get me admitted into Mayo. I cant tell you the number of times they said, no! to her. She then had to navigate Medicare and our secondary insurance policies while being on hold for hours to get our expenses down considerably. She learned the system and got me the best care and insurance coverage possible. Ellen never gave up fighting for me and never took no for an answer.

For 42 straight weeks, they lit me up with chemo causing night sweats, dizzy spells, loss of appetite, reduced oxygen in my blood and days of no energy. All the time, I tried to walk, hike or swim to push those poisons out of my body and keep moving. I only missed about 20 days of working remotely while leading the International Swimming Hall of Fame through Covid, Induction cancellations, closures, and construction disruptions.

Every week Mayo would draw blood to measure my cells and cancer. There were days when my hemoglobin was so low that I needed transfusions.

Over the holidays, I had a reaction to one of my drugs after developing a full-body skin rash. They took me off that drug and my cancer increased.

Then I got Covid! They stopped Chemo for two weeks and gave me a monoclonal covid shot to help me through the virus. After I recovered, the blood tests showed that the cancer was increasing.

I was discouraged as they decided to get more aggressive in February.

They put me back in the hospital and inlaid a three-port line into my chest that tunneled directly into my heart. They wasted no time and infused me through my new ports with 4 different chemotherapies at one time. They let the medicines drip into my veins for 72 straight hours. Then they started giving me another chemo shot in the stomach.

Chemo Blast

Somehow, I found the strength to get out of bed and walk in circles again. Somedays, I got up to 3 miles with Ivan beside me. (Ivan was the name of the IV pole that I pushed around.)

Rutemillers Army Pin

Every nurse along the way got a Rutemillers Army pin as I told them that I was going to be The first person cured of this dreaded cancer. Some of them said they believed me.

After they discharged me, I lost all my hair, but the Chemo Blast treatment was working. The cancer was receding quickly in my blood, but not fast enough.

We were quickly running out of time, so they decided to proceed with harvesting my stem cells to replace the cancer cells in my marrow. My body cooperated by delivering 11.5 million stem cells over two days of harvesting.

The time came on March 16th, to start the stem cell transplant. They hit me with the highest dose of Chemo to wipe out all my marrow producing cells.

Two days later, on March 18th, they infused me with 5.25 million of my own stem cells to take me back to my factory settings and froze the remaining cells. The treatment wiped out all my childhood vaccinations and any other ones in my life. I had no immune system and had to be isolated at home for 30 days as my marrow regenerated.

After 7 days, I unexpectedly vomited after lunch and then developed a fever. Mayo called in the Infectious Disease Team and identified five different bacteria in my blood. The wired me up to a broad-spectrum of antibiotics that wrecked my gut. I stayed in the hospital for five more days.

My red blood and plasma dropped to a critical point forcing two infusions of each. I went home in pain and finally succumbed to a pain killer for the first time, but for only two days.

10 days later the entire family caught norovirus. It took us all four days to recover from severe Gastrointestinal issues.

Since then, I have been getting stronger. Last week marked the 50th day since my transplant. I am back to pre-cancer exercise having swum 3000 yards this morning and hiking in the mountains on Tuesdays and Thursdays with Glenn Mills my Olympic standard.

The Mayo Doctors usually wait 100 days before testing, but because my cancer is so aggressive, they tested me on day fifty.

I was not expecting good news when I got a text from the doctor saying that they COULD NOT FIND ANY CANCER in my blood It is in the normal range!!! (Note he added three exclamation points.). So, after almost one year of positive prayers from everyone, and positive attitudes cheering me on, and regular exercise, I can say that my cancer is in EARLY REMISSION. We did it!!!

We now have the upper hand. Remission for my cancer can last 2-4 years, or longer. The way I see it, with the support of my lovely wife, and with the expertise of Mayo, guidance from my god (who surely got a few words from my mom who passed away 4 days ago), and the support of Rutemillers Army we will reach the goal of FINDING a cure

Brent Rutemiller CEO, President of International Swimming Hall of Fame

Link:
Brent Rutemiller's Cancer In Early Remission After 42 Weeks of Chemotherapy and Stem Cell Transplant - Swimming World Magazine

CHASE BOTTORF/THE EXPRESSLocal relay teams walked in the relay to help spread cancer awareness and help fundraising efforts for the American Cancer Society.

LOCK HAVEN Clinton County recently held its 27th annual Relay For Life in Riverview Park, Woodward Township.

The yearly fundraising event for the American Cancer Society, co-event lead by Roxanne Embick and Shannon Miller, brought in a large crowd with generous donations to boot. Fundraising that is done all foes to the American Cancer Society.

The majority of the money raised stays locally as advocacy for support, according to Roxanne. The other portion of the money goes towards cancer research, she added.

Relay For Life began as a 24-hour ongoing event which always had a member of each relay team walking the track for those 24 hours. The reasoning for the constant 24-hour walking resonates from cancer patients having to live with cancer 24 hours a day, according to Roxanne.

It was in honor of that. Now they have gotten a little relaxed on that but the teams are here and they do walk the track and do fundraisers, she added.

Relay For Life has been a national event since 1985. It has now become more globalized internationally in countries like Canada and Mexico.

Eight relay teams were signed up for 2022s Clinton County Relay For Life with six of those teams participating in this years events.

Not all teams are required to come and set up a site but they do their fundraising through the year, said Roxanne.

The last two years, the Relay For Life coordinators have been trying to catch up due to missing a year with COVID in 2020. Coordinators are hoping to try and make up some of that.

To date, the Clinton County Relay For Life has raised over $30,000. Their ultimate goal is to raise at least a total of $77,000.

Hopefully we can get more people. We can take donations for this year up until August and we do have a couple of events happening throughout the year, Roxanne said.

Cancer survivors attended the day long event with a couple sharing their own stories to the public. Of the survivors whos stories were told, Roxannes own husband, Earl Embick, was a survivor with his own story to tell. In late 2010, he was diagnosed with multiple myeloma.

Roxanne addressed her husbands story to everyone who attended during the survivor event meal.

In November of that year, he woke up in the morning to an upset stomach and a headache. Thinking it was a stomach bug, he tried to go to work but had to leave early due to his sickness, she said. When Earl returned home, Roxanne, who is a nurse, said he had signs of menangitus.

They went to the hospital and discovered that he had bacterial menangitus, a rare form as opposed to the more common viral menangitus, according to Roxanne. However, menangitus would turn out to be part of Earls ailments.

He went through treatment and got better, however it was discovered that his kidneys were not functioning properly, Roxanne said. When we went back to the infectious disease doctor after he was discharged from the hospital, he was concerned and said that he had stage three kidney failure.

Doctors ran tests and found that the protein in Earls urine was four times higher than it should have been, she added. Another test was ran and the results came back positive for multiple myeloma a bone marrow cancer.

There are bad cells in there and they basically over grow, kind of like weeds in a garden. They choke out your ability to make white and red cells and all those things, Roxanne said. It was unusual because most of the time multiple myeloma normally doesnt affect people who are in their forties, which is how old Earl was at the time.

Multiple myeloma typically affects patients who are older in their sixties and seventies. According to Roxanne, there is no understanding of what the root cause of multiple myeloma is.

Since Earl was younger than usual myeloma patients, doctors were able to do the necessary treatments on him. On his 41st birthday in December of 2010, he and Roxanne went to Ohio State University to an oncologist who specializes in myeloma. He received his treatment and was put on two medications, which he took twice a week for eight weeks.

His numbers didnt come down as much has they had hoped but that was okay, Roxanne said about the eight weeks of treatment. In April, we went back for his stem cell transplant. Fortunately they were able to use his own stem cells.

Before his transplant, Earl had to get three shots a day for five days to pack his bone marrow with stem cells. When the transplant was ready to be done, it took six total hours to harvest the stem cells, according to Roxanne.

In May of 2011, he went back to the hospital for high dose chemo therapy and two days later received a rescue stem cell transplant. Though from the transplant, Earl ended up having a complication, according to Roxanne. He had engraftment syndrome which is when stem cells start engrafting and the body sees it as a rejection becoming sick with a high fever.

He made it through everything. He was in the hospital for 17 days we stayed in Ohio until July, Roxanne said. He started maintenance chemo therapy that September called REVLIMID (aka Lenalidomide) he was on that maintenance for six years.

Earl has now been off of all treatments for the last five years and is still without any elements of cancer, she added.

I know as caregivers, we have a very important role to play, we have to be an advocate, we have to make sure theyre getting to their appointments on time and keeping track of them because chemo can make the brain not work like youd like it to work that is all important. He was as much my caregiver as I was his, Roxanne expressed.

The 27th Annual Clinton County Relay For Life lasted from 10 a.m. to 10 p.m. last Saturday and was filled with a whole day of events, spreading cancer awareness. More events through the Relay For Life are set throughout the rest of the year.

Today's breaking news and more in your inbox

Continued here:
Clinton County Relay For Life holds annual event in Riverview Park - Lock Haven Express

There are dozens of studies, innovations, and research findings released everyday by institutions and clinics across the world. Heres a look at some of the other notable health reports from May 17.

Time-Restricted Eating May Lower CVD Risk for Older Breast Cancer SurvivorsOlder breast cancer survivors with cardiometabolic risk factors who restricted food intake to eight hours during the weekday, followed by 16 hours of fasting, lowered their risk of cardiovascular disease (CVD) after a few weeks, according to a new research letter publishing today inJACC: CardioOncology.

Community-Focused Strategy Improves Vaccine Uptake in Black and Latino CommunitiesNew research from Boston Medical Center (BMC) shows how intentionality and partnership between community leaders and medical health centers can improve COVID-19 vaccination uptake in Black and Latino communities.

McMaster researchers discover how to reduce severe tissue damage from some viral infectionsMcMaster University researchers have found not only how some viral infections cause severe tissue damage, but also how to reduce it.

Concussion symptoms in children may have multiple underlying causesResearchers unlock potential pathways for treatment by focusing on the relationships between the symptoms of concussions and the nature of the injury.

mRNA vaccines like Pfizer and Moderna fare better against COVID-19 variants of concernA comparison of four COVID-19 vaccinations shows that messenger RNA (mRNA) vaccines Pfizer-BioNTech and Moderna perform better against the World Health Organizations variants of concern (VOCs) than viral vector vaccines AstraZeneca and J&J/Janssen.

New tool developed by WVU researchers makes it easier to identify pregnant patients with eating disordersAt least 5%of pregnant women will experience aneating disorderduring their pregnancies, yet no rapid screening tool exists to identify who they are.

Organic polymeric scintillators excite X-ray communityEfficient strategy for metal-free polymeric scintillators with multicolor radioluminescence for high-resolution X-ray imaging opens a new avenue of research for low-cost, flexible radioluminescent polymeric materials.

Many historically redlined California communities have higher COVID-19 incidence and mortalityOne of many legacies of redlining could also be increased incidence and mortality charges of COVID-19 affecting the largely minority and poor residents of those neighborhoods, in response to analysis printed on the ATS 2022 worldwide convention.

Scientists Use Machine Learning Models to Help Identify Long COVID PatientsClinical scientists used machine learning (ML) models to explore de-identified electronic health record (EHR) data in theNational COVID Cohort Collaborative (N3C), a National Institutes of Health-funded national clinical database, to help discern characteristics of people with long-COVID and factors that may help identify such patients using data from medical records.

IOMF-funded study determines orgasmic meditation is more comparable to meditation than sexNew research supported by theInstitute of OM Foundation (IOMF), based in Santa Rosa, CA, documents the profoundly positive effect of Orgasmic Meditation, commonly known as OM, for many looking to achieve the overall benefits of meditative practice, according to IOMF-backed researchers.

COVID-19s devastating toll: An rise in adolescent mental health crises and suicidalityA new study led byPatricia Ibeziako, MD, associate chief of clinical services in theDepartment of Psychiatry and Behavioral Servicesat Boston Childrens Hospital, shows that the situation worsened with the onset of the COVID-19 pandemic.

Private Health Plans During 2020 Paid Hospitals 224 Percent of What Medicare Would PayPrices paid to hospitals during 2020 by employers and private insurers for both inpatient and outpatient services averaged 224 percent of what Medicare would have paid, with wide variation in prices among states, according to a new RAND Corporationreport.

Henry Ford Cardiologist to Perform a Live Heart Procedure at International Medical Education EventFor the third straight year,Henry Ford Hospital interventional cardiologist Khaldoon Alaswad, M.D.will perform a live heart procedure as part of an international interactive medical education event, with proceeds benefiting hospitals in Ukraine.

Infrared imaging to measure glymphatic functionDynamic infrared tracer imaging uses affordable and widely available equipment to obtain the temporal resolution necessary to evaluate glymphatic flux within the brain.

Scientists See Signs of Traumatic Brain Injury in Headbutting MuskoxScientists at the Icahn School of Medicine at Mount Sinai saw for the first time hallmarks of concussions and other head trauma in the brains of deceased headbutting animalsmuskoxen and bighorn sheep.

Statins may provide protection against depressionStatins have been hailed as a wonder drug; the cholesterol-lowering drugs have been prescribed to tens of millions of people since their approval in the late 1980s to prevent heart attack and stroke.

Predictable Home Environment Protects Against Development of Heart Disease Risk Factors After Child AbuseA new study shows for the first time that well-organized households protect children who have experienced abuse from developing some precursors to heart disease.

Alternative to open heart surgery just as effective for patients with common heart conditionA study led by researchers at theNational Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centrehas shown that a less invasive heart procedure for a common condition is just as effective as conventional open-heart surgery.

Milestone clinical study shows postbiotic urolithin A improves muscle strength and exercise performance in middle-aged adultsNew research by scientists in Switzerland shows supplementation with urolithin A had exercise-like effects on muscle strength, improving it by 12% after 4 months.

Protein linked to intellectual disability has complex roleResearchers at Washington University School of Medicine in St. Louis have identified a previously unknown function for the fragile X protein, the loss of which is the leading inherited cause of intellectual disability.

Scientists Nail Down Destination for Protein That Delivers ZincDiscovery reveals a key mechanism that all living things use to transport a trace element essential for survival.

Guidelines to ensure assessment of patient symptoms and quality of life is ethicalIna new studypublished inJAMA, experts in the Universitys Centre for Patient Reported Outcomes Research with international collaborators, set out the guidelines, designed to ensure clinical research which includes patient-reported outcomes is ethical, inclusive, equitable and optimal.

Big study answers treatment question for little known kidney conditionThe largest ever randomised controlled trial in IgA nephropathy has found that treatment with methylprednisolone a cheap, widely used corticosteroid drug halves the risk of losing kidney function and kidney failure, and that this can be effectively achieved with fewer side effects if a reduced dose is used.

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020In this study, the cohort of 2020 novel drug approvals continued a trend of new drugs being supported by smaller numbers of preapproval pivotal trials and fewer features traditionally associated with rigor.

Association of Congenital and Acquired Cardiovascular Conditions With COVID-19 Severity Among Pediatric Patients in the USIn this cohort study of 171416 US individuals aged 2 months to 17 years with SARS-CoV-2 infection, cardiac arrest, cardiogenic shock, heart surgery, cardiopulmonary disease, heart failure, hypotension, nontraumatic cerebral hemorrhage, pericarditis, and biventricular defects were associated with increased COVID-19 severity.

Evaluation of Age Patterns of COVID-19 Mortality by Race and Ethnicity From March 2020 to October 2021 in the USAll analyses for this cross-sectional study were conducted using provisional monthly data for March 1, 2020, through October 31, 2021, from the National Center for Health Statisticsand monthly population estimates for 2020 and 2021 from the US Census Bureau.

Desktop Air Curtain System Prevents Spread of COVID-19 in Hospital SettingsIn efforts to prevent the spread of COVID-19, miniaturizing air curtains for hospital wards, labs, and other health care settings is gaining traction as a viable solution to inadequate face masks or when social distancing is not a realistic option.

Phage Therapy: A Model to Predict Its Efficacy against Pathogenic BacteriaResearchers from Inserm, Universit Sorbonne Paris Nord and Universit Paris-Cit at the IAME Laboratory, in close collaboration with their counterparts at Institut Pasteur and the Paris Public Hospitals Group (AP-HP), have developed a model to better predict the efficacy of phage therapy and possibly develop more robust clinical trials.

Prediabetes and Diabetes Screening Eligibility and Detection in US Adults After Changes to US Preventive Services Task Force and American Diabetes Association RecommendationsThe US Preventive Services Task Force (USPSTF) and the American Diabetes Association (ADA) recently recommended lowering the starting age for diabetes screening to 35 years to facilitate earlier detection and treatment.

Study identifies first cellular chaperone for zinc, sheds light on worldwide public health problem of zinc deficiencyThe findings, reported in the journalCell, shed light on the public health issue of zinc deficiency and open an entirely new area of biology for exploration.

University Hospitals and UC Irvine announce new co-leadership of BravNet, a practice-based integrative medicine research networkUniversity Hospitals(UH)Connor Whole Health and Susan Samueli Integrative Health Institute (SSIHI) at University of California, Irvine have joined in collaboration to leadBraveNet the first and largest whole health, practice-based research network in the U.S. BraveNet is a nationwide consortium comprised of academic health systems conducting evidence-based research on therapies used in integrative medicine, which is now more often known as whole health.

ATP from sensory neuron-interneuron crosstalk is key to spreading inflammation in Rheumatoid ArthritisA team of researchers from Japan and the USA, led by Professor Masaaki Murakami at Hokkaido University, have revealed that remote inflammation spreads by neuron crosstalk, and that adenosine triphosphate (ATP) plays a key role in this process.

Density, Benign Disease Raise Risk of Breast CancerWomen with dense breast tissue and benign breast disease face an elevated risk of future breast cancer and could benefit from a tailored mammogram screening strategy, according to a large study published inRadiology.

Choroid Plexus Volume Linked to Alzheimers DiseaseIncreased volume of the brains choroid plexus is linked to greater cognitive impairment and Alzheimers disease, according to a new study published inRadiology.

Geisel Researchers Receive $4 Million Grant to Improve Office Visit Interactions Between People Living with Dementia, Care Partners, and CliniciansA team of researchers at Dartmouths Geisel School of Medicine and New York University (NYU) Grossman School of Medicine has received a $4 million grant from the National Institute on Aging to improve triadic interactions between patients living with dementia, their care partners, and their clinicians.

Untapped Potential: Mineral Water Derived from Deep-Sea Water May Have Health BenefitsScientists determine the biological effects and most beneficial hardness of extract-added water derived from deep-sea water.

First U.S. study analyzing tooth survival after root canal in general populationTeeth survive about 11 years after a root canal, according to new research from Regenstrief Institute and Indiana University School of Dentistry.

Fighting COVID-19: Machine learning to optimise filtration effectiveness of face masksResearchers from the Agency for Science, Technology and Research (A*STAR) have successfully used machine learning in a study to improve the filtration effectiveness of Egyptian Cotton (EC) face masks.

University of Minnesota technology allows amputees to control a robotic arm with their mindUniversity of Minnesota Twin Cities researchers have developed a more accurate, less invasive technology that allows amputees to move a robotic arm using their brain signals instead of their muscles.

Molecular probe links high-fat diet to nitric oxide levels, cancer developmentResearchers at the Beckman Institute deployed a molecular probe to demonstrate a direct link between a high-fat diet and heightened nitric oxide levels, which can lead to increased risk of inflammation and cancer development.

NEW: EULAR Publication on Therapeutic Drug Monitoring in People with Rheumatic DiseaseTherapeutic drug monitoring (TDM) refers to the principle of using blood concentrations of biopharmaceuticals to guide therapeutic decisions. EULAR the European Alliance of Associations for Rheumatology has developed a set of new points to consider to support TDM in people with inflammatory rheumatic and musculoskeletal diseases (RMDs).

Steps Should Be Taken Now to Protect Future Supplies of Infant and Pediatric FormulaA perspective published today in the American Society for NutritionsAmerican Journal of Clinical Nutritionaddresses the shortage of infant and pediatric formulas and offers recommendations to help prevent future occurrences and regain the publics trust in the safety and supply of infant and pediatric nutrition.

The war in Ukraine impacts patients with mental disordersDanish patients with mental disorders seem to have experienced a worsening of symptoms in connection with the invasion of Ukraine.

3D-printed acoustic holograms against Alzheimers or ParkinsonsA team from the Universitat Politcnica de Valncia (UPV), the Spanish National Research Council (CSIC) and Columbia University (US) has created 3D-printed acoustic holograms and evaluated their potential in animal models to improve the treatment of diseases like Alzheimers and Parkinsons, among others.

HBP researchers reveal how the volumes of brain regions change in Parkinsons diseaseResearchers of the Human Brain Project (HBP) found that in Parkinsons disease the volumes of certain brain regions decrease over time in a specific pattern that is associated with clinical symptoms and largely coincides with the pattern described in Braaks famous staging theory.

Landmark Externally-Led Patient-Focused Drug Development Meeting on Schizophrenia Will Showcase Urgent Need for New & Better TreatmentsPeople living with schizophrenia and other psychosis spectrum disorders are too often misunderstood or ignored, and current treatments are outdated and can cause significant side effects.

Nearly half of patients at high risk for lung cancer delayed screening follow-upPreliminary studies to track patients perceived risk of developing lung cancer after a CT scan found that 47 percent had delayed care, according to a study published at the ATS 2022 international conference.

A highly sensitive detection strategy for biomarkers with controllable dynamic rangeIn this research, droplets motion behaviors on the surface were precisely controlled by adjusting the hydrophobic interaction between DNA droplets and lubricant-infused micro-grooves structural surface.

For large bone injuries, its Sonic hedgehog to the rescueA USC Stem Cell study innpj Regenerative Medicinepresents intriguing evidence that large bone injuries might trigger a repair strategy in adults that recapitulates elements of skeletal formationin utero.

New guideline refines care for brain bleeds: compression socks, some meds not effectiveSome treatments or preventive therapies used to manage intracerebral hemorrhages (ICH), or a bleedingstroke, are not as effective as previously believed, according to the new American Heart Association/American Stroke Association guideline for caring for people with spontaneous ICH, published today in the AssociationsStrokejournal.

Marking World Hypertension Day and emerging data on renal denervation: Three renal denervation trials point to effective long-term treatment of hypertensionMay 17th is World Hypertension Day whose theme Measure Your Blood Pressure Accurately, Control It, Live Longer is aimed at increasing awareness of hypertension worldwide.

2022 Andreas Grntzig Ethica Award: The Nursing and Allied Professional Community, at the heart of cardiovascular careOn the 19th of May the Andreas Grntzig Ethica Award, the highest honour in the interventional cardiology community, will be awarded at EuroPCR 2022 to the Nurses and Allied Professionals community in recognition of the essential role they play in advancing the cardiovascular field, serving in a substantial and immediate way the needs of each individual patient.

Climate action, pandemic preparedness and One Health: Science academies present statements for G7 summitAt the Science7 Dialogue Forum in Berlin/Germany on Tuesday, 31 May, the science academies of the G7 states will publish science-based statements on topics on this years agenda of the G7 summit at Schloss Elmau/Germany.

Nature Cardiovascular Research: A CNIC team creates a dynamic 3D atlas of embryonic heart formationResearchers from theNational Center for Cardiovascular Research (CNIC) have created a 3D atlas of the process of heart formation in its embryonic phase, from a collection of mouse samples.

New health professional training blueprint to transform chronic pain careResearchers have developed a new national blueprint to help health professionals support the one in five Australians living with chronic pain, costing the Australian economy $139 billion every year.

NIR-II-Responsive Nickel-Based Therapeutics Provide New Solution for Synergistic OncotherapyA polyethylene glycol-modified urchin-like nickel nanoclusters (PUNNC) with an applied 9T magnetic field, when used for photothermal enhanced chemodynamic synergistic therapy under near-infrared (NIR)-II radiation, can efficiently kill tumor cells in vitro and inhibit tumor tissue growth in vivo, according to a paper published onTheranosticsrecently.

Study uncovers biomarkers that predict response and side effects from immunotherapy for liver cancer patientsA research team from Singapore has identified novel biomarkers that not only predict a patients response to immunotherapy, but also the adverse events they may experience from the same immunotherapy used to treat primary liver cancer hepatocellular carcinoma (HCC).

Change of temperature causes whole body reprogrammingUNIGE scientists have discovered that changes in temperature cause marked and organ-specific effects in all tissues.

See the article here:
Other Notable Health Studies & Research From May 17, 2022 - Study Finds

Sure. Why Not? I mean, we've got record-high gas prices, supply shortages, the lingering effects of a pandemic, political unrest, and a war in Europe--so why not throw in an invasive species of worm that can leap into the air. Weneeded something else to worry about.

Did I mention that these jumping worms have giant talons and teeth that are capable of ripping an adult human to shreds in less than 30 seconds?

No? Well, that's good, because they don't, and I would hate to lie to you for extra clicks.

University of Illinois Extension, Facebook

University of Illinois Extension, Facebook

It's also in 40 states and counting, so it's not just an Illinois, or even Midwestern problem. What jumping/crazy/snake worms do is absolutely devastate soil, which can and will pose a huge problem for farms, gardens, forests, and every other sort of ecosystem dependent on the earth itself for sustenance.

According toSmithsonianMag.com:

After jumping worms feed their insatiable appetites, they leave behind loose, granular soil the texture of coffee grounds. This altered soil can no longer retain moisture, lacks nutrients and quickly erodes.

Janetta Rightnowar, Facebook

University of Illinois Extension, Facebook

University of Illinois Extension, Facebook

Maybe you're a hardcore gardener with a wide variety of plants, vegetables, flowers, and more. You'll want to be careful about dividing up and moving perennials because you can make the jumping/crazy/snake worm problem worse.

Extension.Illinois.edu:

Much to the dismay of generous gardeners as well as organizations selling shared perennials, spread of this invasive species can also happen quickly through dividing and moving perennial plant species. Spring is often the time of plant sales and sharing perennials, this practice can be harmful to private yards and gardens, as well as forested land.

Click here to learn more about these invasive pests from the University Of Illinois Extension.

Remember when you had a summer break?

To prepare yourself for a potential incident, always keep your vet's phone number handy, along with an after-hours clinic you can call in an emergency. The ASPCA Animal Poison Control Center also has a hotline you can call at (888) 426-4435 for advice.

Even with all of these resources, however, the best cure for food poisoning is preventing it in the first place. To give you an idea of what human foods can be dangerous, Stacker has put together a slideshow of 30 common foods to avoid. Take a look to see if there are any that surprise you.

Visit link:
Illinois Is Being Invaded By Worms That Jump A Foot In The Air - 1440wrok.com

Billionaire businessman Tilman Fertitta said he has always been a strong believer in the University of Houston medical schools mission to improve health care equity in Texas. Now hes donating $50 million to help make that vision a reality.

Fertitta and his family on Thursday announced what UH leaders say is a transformational donation for the fledgling medical school, which welcomed its first group of students just two years ago. In recognition, the school has been named the Tilman J. Fertitta Family College of Medicine, as it prepares to open a state-of-the-art, $80 million building this summer.

Fertitta, the owner of the Landrys Inc. hospitality empire and the Houston Rockets, played a critical role in establishing the medical school as the longtime chairman of the UH systems board of regents. But its the schools mission to improve health and health care in the community that inspired him to make such a large donation, he said.

Everybody should have the same medical treatment that anybody else has, he said. Thats one of the things that I like about this school, and where were trying to fit into the community. We want people to have good primary care, to take care of whatever you need to take care of.

The University of Houston's medical school will be named the Tilman J. Fertitta College of Medicine in recognition of the Fertitta Family Foundation's $50 million donation.

The University of Houston's medical school will be named the Tilman J. Fertitta College of Medicine in recognition of the Fertitta Family Foundation's $50 million donation.

The University of Houston's medical school will be named the Tilman J. Fertitta College of Medicine in recognition of the Fertitta Family Foundation's $50 million donation.

The school was founded in 2019 with a curriculum that emphasizes community health, behavioral and mental health, preventative medicine and social determinants of health the social and economic conditions that influence individual and community health.

The goal is for 50% of graduates to choose careers in primary care specialties, such as pediatrics and general internal medicine, to help address a shortage in Texas. The states Department of State and Human Services has estimated there will a shortage of 3,375 primary care physicians by 2030.

Improving health and health care equity have always been important issues in the medical community, which is why the school has focused on those areas from the outset. But the COVID-19 pandemic and the social justice movement have made them front-burner issues to a larger group of Americans, said Dr. Steven Spann, the medical schools founding dean.

This is something we were thinking about. This is our mission, Spann said. Its wonderful to see society, and health care in particular, beginning to understand the importance of that and embrace it.

The school is also focused on improving the diversity of physicians. Of the 60 students who have been part of the schools first two classes, 67% are from groups that are underrepresented in medicine, and more than half came from a lower socioeconomic background, according to a news release. By comparison, just 13% of students admitted to U.S. medical schools each year are Black or Hispanic.

Training the next generation of primary care physicians and improving health care equity are goals that go hand-in-hand, said Dr. Toi Harris, senior vice president and chief equity, diversity and inclusion officer for Memorial Hermann. If a medical school student has an opportunity to train in a primary care setting, it could help them understand how social determinants, such as socioeconomic status or access to education, affect a patients overall health.

I think its tremendously helpful and will be impactful in terms of how they approach patient care and how they engage with the community, Harris said. Gaining exposure to these types of models during training really can help inform your career pursuits and the way you deliver care.

NEWSLETTERS

Join the conversation with HouWeAre

We want to foster conversation and highlight the intersection of race, identity and culture in one of America's most diverse cities. Sign up for the HouWeAre newsletter here.

In his role as chairman of the UH board of regents, Fertitta has been aligned with the medical schools mission to improve health care access and equity from the start, university President Renu Khator said.

He really believes in its future and what it could do. He has a very clear idea of where it could be in 10 years, or where it could be in 15 years, she said. For him to come forward and give this kind of gift to help the medical school take off and be something better than what it would be without these kinds of transformational gifts, its amazing.

The $50 million donation will go toward efforts to hire top-notch faculty and invest in research at the medical school, Khator said.

Tilman Fertitta, owner of Landry's, Inc., and the Houston Rockets, poses for a portrait at the Post Oak Hotel at Uptown on Tuesday, May 28, 2019, in Houston.

Heres how the gift will be divided:

$10 million will go toward five endowed chairs; the school intends to hire renowned scholars who are focused on health care innovation. This $10 million will be matched as part of the universitys $100 Million Challenge for chairs and professorships.

$10 million will be used to establish an endowed scholarship fund to support endowed graduate research stipends and fellowships for medical students.

$10 million will go toward covering start-up costs for the medical school to enhance research activities.

$20 million will be used to create the Fertitta Deans Endowed Fund to support research-enhancing activities.

Fertittas donation also kicks off a $100 million fundraising campaign for the medical school. The money will be used to support scholarships, recruit faculty and pay for operational needs, such as equipment.

This isnt the first time Fertitta, a UH alum, has given a substantial donation to his alma mater. Back in 2016, he donated $20 million to help fund a $60 million renovation of the universitys basketball arena, now known as the Fertitta Center.

The University of Houston's medical school will be named the Tilman J. Fertitta College of Medicine in recognition of the Fertitta Family Foundation's $50 million donation.

The University of Houston's medical school will be named the Tilman J. Fertitta College of Medicine in recognition of the Fertitta Family Foundation's $50 million donation.

The University of Houston's medical school will be named the Tilman J. Fertitta College of Medicine in recognition of the Fertitta Family Foundation's $50 million donation.

I love Houston. Houstons been very good to me. And the university is the namesake of our city, Fertitta said. Its one of the few large public universities that are in a city the size of Houston, and thats what makes it special.

As chairman of the board of regents, Fertitta led the effort to select a site for the new $80 million College of Medicine building. The board decided in 2018 to build the 130,000 square foot building on a 43-acre tract of previously undeveloped campus land. The building is part of a planned life sciences complex along Martin Luther King Boulevard.

The medical school welcomed its first class of 30 students in 2020. For the past two years, the colleges temporary home has been the Health 2 building on campus.

The new building features a state-of-the-art anatomy suite, a clinical skills lab, patient examination rooms, a simulation center and large team-based learning classrooms.

Fertittas donation is a morale-booster for the medical school as the new building is set to open this summer, Spann said.

We have this beautiful new building, and we now have a great name on our medical school, he said. It just builds momentum and builds enthusiasm. It will foster community support.

Fertitta is also hopeful that his familys donation will inspire others to support the medical school and its mission. He knows that his donation and the work being done at the medical school are just the start; further investments will be needed to improve health care equity in Texas and elsewhere in the U.S.

However, hes hopeful the $50 million donation will help to accomplish that goal. No one should have to spend 10 hours in an emergency room on a Saturday because they dont have a primary care doctor, he said.

This is going to be something thats extremely special, he said. You just have to have the vision to look into the future.

Read more here:
Tilman Fertitta donating $50 million to UH medical school, which will be renamed after him - Houston Chronicle

After 34 years serving Foxboro and the surrounding communities, Dr. Joseph Horan is retiring from family practice on May 25, 2022. A

fter spending his childhood in Readvilleand attending Xaverian Brothers High School, he attended St Francis Xavier University in Nova Scotia, Canada and then completed medical school at Dalhousie University in 1985. He completed his residency in family practice at UMass family medicine in Fitchburg and in 1988, after moving to the area with his family, he started at the Foxboro Area Health Center. He remains as part of the community now, where three of his grandchildren reside.

Despite the many difficulties that primary care physicians face, Dr. Horan has always remained true to himself -- putting his patients above all else. The role of a family practitioner is really to be a Jack of all Trades for patients from cradle to grave, and this is what Dr. Horan is. They are responsible for preventative care including yearly physicals and vaccines, but are also the first call when someone feels sick or notices something is wrong. They are cardiologists, gastroenterologists, dermatologists, neurologists, psychologists and much more. But maybe most importantly, they are advocates, which is a role Dr Horan has always taken very seriously throughout the years.

From squeezing another patient into his always jam-packed schedule, visiting an elderly patient in the comfort of their own homes, fielding phone consults from friends and family and beyond, or extending his condolences to families who have lost their loved ones who he cared for during his entire career, Dr. Horan always went the extra mile. It is impossible for his family to count the number of stories heard and times they witnessed him going above and beyond for his patients to get the care they need and support them as they navigated some of the scariest times of their lives.

Growing up in the town where he practiced, a week did not pass without his children hearing your dad is my doctor from someone in the community, and often his wifes five-minute grocery run would become a 30-minute conversation with one of his patients. But even though he had so many responsibilities in his practice, he never missed a chance to see his kids play sports, or perform in the band, or spend time skiing with them on the weekends.

Many of his patients had such kind words to share. One family he cared for over 30 years who had two children with intense medical needs described him as a witness to their lives, someone who never tired of helping us, always a phone call away. The many nurses and medical staff that worked with him throughout the years cherished their time working with him and described him as a brilliant and caring man, who never rested until he knew what was wrong with his patient.

Dr. Horan has considered it a great privilege and honor to have cared for so many generations of local families. While he is looking forward to the next chapter of his life, he has been humbled by the many cards, emails and gifts he has received as an expression of appreciation. This community has been touched by a great doctor and his quality care will be greatly missed. They truly dont make doctors like Dr. Horan anymore.

The author of this column, Pam Morrison, is the daughter of Dr. Joseph Horan

Originally posted here:
Dedication, generosity and compassion that had no limit! - The Sun Chronicle

The first time a PC seemed magical to me was when it dozed off and colourful lines twisted across its screen. I'd launch Windows 3.1 just to watch screensavers, marvelling at Mystify and staring at Starfield. How wonderful that our computer needed to dream as preventative medicine! I relived this today with a new collection of customisable 3D screensavers, watching shoals of fish, taking a road trip through a museum of global electricity pylons, watching housing estates rise and fall, and seeing so many swirly colours.

Made by Jean-Paul Software (aka our very own RPS commenter, "Godwhacker"), The Jean-Paul Software Screen Explosion launched this week after a few months in early access. It packs 11 screensavers including a swirling shoal of fish, procedural models of housing estates coming together and breaking apart, a clockwork countdown to your estimated time of death, a vast warehouse run by Father Christmas and his reindeer, and a wild warpspeed starfield. Some have options to customise colours and such, and some even let you add your own custom models (or download others' through the Steam Workshop).

My personal favourite is Pylons Of The World, an endless drive along a colourful road criss-crossed by electricity pylons from around the globe. Yes, it tells you the origin of the pylons you're seeing. And yes, it drives on the left side of the road where appropriate.

I've not used a screensaver in years. They're not needed anymore, and my monitors automatically turn off when idle to save power anyway. Running 3D scenes which make my computer use more power when idle is the opposite of what I want. And yet. While I won't start using a screensaver now, I did enjoy playing with screensavers today.

I enjoyed restarting screensavers to see them with new colours or new patterns. I really enjoyed that drive past international pylons. I enjoyed watching colours. I felt the childhood magic of screensavers again.

The Jean-Paul Software Screen Explosion is out now on Steam for 4/4/$5.

The second time a PC seemed magical to me was the cascade after I won Solitaire for the first time.

Read the original post:
This new 3D screensaver collection includes a driving tour of global pylons - Rock Paper Shotgun

Reestablishing a strong doctor-patient relationship

During Dr. Priester's tenure as internist and cardiologist in New York, he has built enduring relationships with his patient base, many of whom have been loyal to him for several decades. As his practices continued to grow, so did the administrative demands of operating and maintaining a private practice.

Like many other private internal medicine physicians, Dr. Priester has found himself at a crossroads: either continue to practice high-volume medicine, seeing many patients a day, but spending a limited amount of time with each of them or let his practice evolve to deliver highly personalized, preventative care and a chance to empower his patients with greater education and information.

The Priester CCPHP Membership

The concierge (membership-based) model continues to be a rewarding experience for physicians and patients alike. The increased time and flexibility allow concierge physicians, like Dr. Priester, to schedule patients for an hour appointment, if desired.

I've always believed in the importance of the doctor-patient relationship," says Dr. Priester. "This concierge model will not only support that relationship, but allow it to go one step further, by allowing more time with each patient."

Concierge patients of Priester CCPHP receive a host of added amenities as Members, including 24/7 connectivity to Dr. Priester via a direct phone number and a customized telehealth app, same/next day appointments with limited to no wait times regardless of medical necessity, and a robust wellness program called the SENS Solution Wellness Program powered by CCPHP, which focuses on Sleep, Exercise, Nutrition, and Stress Management.

Through the partnership with CCPHP, Dr. Priester also has access to Castle Connolly's Top Doctor Network of nearly 60,000 top recognized physicians nationwide. Being a recognized Top Doctor himself, Dr. Priester can consult with and refer patients to top physicians of similar distinction.

About Dr. Priester

William D. Priester, MD is a board-certified internist and cardiologist serving the community of New York, NY. Dr. Priester earned his Doctor of Medicine from the University of Iowa and completed his internship and residency in internal medicine at Metropolitan Hospital in New York. He completed his fellowship in cardiology at Lenox Hill Hospital, where he continues as an Adjunct Attending Physician.

Learn more about Dr. Priester's concierge program, Priester CCPHP:

About CCPHP

Castle Connolly Private Health Partners (CCPHP) works with exceptional physicians to create and support concierge (membership-based) healthcare programs that enable the optimal practice environment and the physician-patient relationship. Members (patients) pay an affordable fee to take advantage of a wide array of enhancements for a more convenient, comprehensive, collaborative, and personalized approach to support health and wellbeing. For more information, go toccphp.net.

SOURCE Castle Connolly Private Health Partners, LLC

See the article here:
Manhattan internist and cardiologist, Dr. William Priester collaborates with Castle Connolly Private Health Partners to create a new concierge medical...

The human immunodeficiency virus (HIV) has remained a significant challenge for researchers as there is currently a lack of cure or vaccine for this disorder.

Image Credit:PENpics Studio/Shutterstock.com

While antiretrovirals have improved the types of therapy available for patients, the ineffective requirement of lifetime treatment, as well as the development of resistance, is a major hurdle. However, the emergence and growth of nanotechnology may be a promising solution for a higher level of effective treatment as well as prevention of both HIV and acquired immunodeficiency syndrome (AIDS).

HIV was first identified in 1983 as the causative agent that resulted in AIDS, which was first reported in 1981.

The progression of the virus and the associated disease has been reported to be a global pandemic as one of the global lead causes of mortality in adults. The World Health Organization (WHO) has estimated the number of people living with HIV in 2020 was approximately 37.7 million; this can be translated as 0.7% of the global population, with Africa comprising the highest prevalence compared to other continents.

This majorly infectious disease consists of a primary strain, HIV-1, that can be traced to the chimpanzee species. This virus is an enveloped retrovirus that consists of two copies of single-stranded RNA.

There are three distinct stages of HIV, which describe the progression of the virus, including acute HIV infection, chronic HIV infection, and AIDS.

These can be summarized as the multiplying of the HIV virus, including the initial rapid destruction of CD4 T lymphocytes within the host, causing flu-like symptoms. This can then progress into the second asymptomatic stage, where the virus continues to multiply at low levels; within this chronic stage, the infection can progress into AIDS in 10 years or longer without antiretroviral therapy.

The final stage of HIV consists of AIDS, which is the most severe stage of the infection and can be characterized as having a high level of damage to the immune system, where the body is unable to fight against opportunistic infections. A diagnosis of AIDS is made when HIV patients have a CD4 count of 200 cells/mm3.

HIV/AIDS treatments have focused on antiretroviral therapies, with early treatment being only effective to a certain extent; the first drug that was FDA approved was in 1987, and since, approximately 25 drugs have received approval.

The progression of research, which included the release of protease inhibitors as well as the emergence of triple-drug therapy within the mid-1990s was highly promising for the efficacy of HIV/AIDS treatment. Currently, the highest standard of HIV/AIDS treatment consists of highly active antiretroviral therapy, involving three or more drugs provided simultaneously.

With further research into disease prevention strategies, vaccines have been considered the most effective agent for fighting global infections, evidenced by efficient control over infectious diseases such as measles, mumps, and rubella.

The challenges that can be associated with this chronic disease consist of requiring patient compliance for lifetime treatment, which can be difficult to adhere to. A lack of adherence to treatment can increase the probability of treatment failure and increase the likelihood of developing resistant strains of the virus.

Another limitation includes poor aqueous drug solubility, as this can impact the availability of the drug within the body and result in ineffective treatment of HIV.

The advancement in nanotechnology and nanomedicine has provided a promising future for HIV/AIDS therapeutics.

With the advancement of nanomedicine, strategies have been explored to overcome current challenges associated with HIV treatment. This includes oral administration of antiretroviral drugs and improving the water solubility of drugs, such as through solid drug nanoparticles (SDN).

Research into SDN formulations has been produced through a freeze-drying approach, which has been predicted to provide a similar pharmacokinetic standard as a conventional anti-HIV drug. However, this nanomedicine formulation was theorized to allow patients to take a 50% lower dose while experiencing the same effect. This prediction was validated with in vivo experimentation.

The development of SDN formulations has enabled success in superseding conventional oral drug formulations, such asritonavir-boosted lopinavir, which utilizes 42% ethanol and 15% propylene glycol. The use of lopinavir SDN formulations can achieve the production of an effective oral drug without the inclusion of ethanol.

Additionally, the potential inclusion of nanomedicine within this field of therapeutics allows for low-cost production of effective drugs as well as a decrease in required doses for patients.

Other subsets of nanomedicine that can be used for HIV therapeutics include long-acting injectable formulations (LAI), which can provide a solution to patient issues associated with low adherence to lifetime treatments.

An example of a drug that has been re-formulated to carry a nanomedicine component includes the non-nucleoside reverse transcriptase inhibitor, rilpivirine, which has been available as an oral medication from 2011, before being nanoformulated as a LAI.

This LAI nanomedicine has been proven to be effective, with concentrations being detected in rats up to 2 months after subcutaneous and intramuscular administration as well as detected in dogs for up to 6 months after administration.

New research in this area has included the Herbert Wertheim College of Medicine(HWCOM), who have undertaken nanotechnology research into the delivery of anti-HIV drugs across the blood-brain barrier, aiding in targeting HIV reservoirs within the brain. This research has included the development of a revolutionary technique consisting of using tiny magneto-electric nanoparticles as drug carriers.

Nagesh Kolishetti, one of the studys corresponding authors, stated, This delivery system can reduce the viral load, the amount of virus present, which normally contributes to neurological problems.

This type of combination therapy with the nanoparticles could result in a highly effective treatment regimen for the HIV-infected population who are addicted to a substance of abuse.

This is significant as HIV can cause neurological problems and disorders such as dementia and memory loss, which can be further increased by substance abuse

The future of HIV therapeutics can be said to be greatly intertwined with nanomedicine, with research into the use of nanoformulations that attempt to overcome the challenges of current HIV treatments.

With reports from WHO stating that 73% of HIV patients are treated with antiretroviral therapy and 680,000 deaths in 2020, this field requires a revolutionary change to traditional medicine to provide better treatment and even preventative care for this chronic disease.

Curley, P., Liptrott, N. and Owen, A., 2018. Advances in nanomedicine drug delivery applications for HIV therapy.Future Science OA, 4(1), p.FSO230. Available at: 10.4155/fsoa-2017-0069

FIU News. 2022.Researchers advance the use of nanoparticles to deliver HIV/AIDS drugs to the brain. [online] Available at: https://news.fiu.edu/2021/fiu-researchers-advance-the-use-of-nanoparticles-to-deliver-hivaids-drugs-to-the-brain

Hivinfo.nih.gov. 2022.The Stages of HIV Infection | NIH. [online] Available at:https://hivinfo.nih.gov/understanding-hiv/fact-sheets/stages-hiv-infection

Mamo, T., Moseman, E., Kolishetti, N., Salvador-Morales, C., Shi, J., Kuritzkes, D., Langer, R., Andrian, U. and Farokhzad, O., 2010. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.Nanomedicine, 5(2), pp.269-285. Available at: 10.2217/nnm.10.1

Worldpopulationreview.com. 2022.HIV Rates by Country 2022. [online] Available at: https://worldpopulationreview.com/country-rankings/hiv-rates-by-country

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

Read the rest here:
Nanomedicine and HIV Therapeutics - AZoNano

Whether youre planning summer activities at home or abroad, it is important to think about ways to avoid seasonal mosquitos if you want to ensure your recreational activities remain enjoyable. Besides the itchy and painful bites mosquitos leave behind, they can carry diseases that are easily transmitted to humans.

While the bites and infections they spread can often be treated, the best course of action is to prevent the bites altogether. If you have control of the environment and can think ahead, there are several ways you can sidestep the pests.

A good place to start is to make sure you have screens to block mosquitos from coming indoors and to be sure to eliminate standing water, where they can lay eggs. When evaluating for standing water, dont forget to check flower pots, rain gutters, plastic furniture covers, and toys.

If you are out and about, wearing long pants and sleeves can help cover bare skin, which gives mosquitoes easy access. In areas of high mosquito concentrations, treating clothing with permethrin, an anti-parasite cream, adds additional protection. While there are a number of different topical products on the market that claim to repel mosquitos, the validity of these claims is not always the same across brands. When looking for safe and effective ways to prevent mosquito bites, there are some products that demonstrate both safety and efficacy.

DEET is most strongly recommended by the Centers for Disease Control and Prevention and the Environmental Protection Agency (EPA). Some recommended alternatives to DEET are Picaridin and IR3535. While there are many natural mosquito repelling products, unfortunately, most have not been shown to be effective. The exception to this is oil of lemon eucalyptus, which has an efficacy comparable to DEET.

To be sure the product you would like to use is appropriate, the EPA has a free search tool that allows you to find specific products that will repel mosquitos, ticks, or both. When evaluating products, use caution with treated wristbands. Even though these may contain mosquito-repelling agents, they dont provide a wide enough protection zone to provide adequate coverage for the whole body.

And if your plans include international travel, scheduling an appointment with your physician is important to discuss ways to avoid mosquitos, as well as to obtain preventative medications for mosquito-borne illnesses. While mosquitos are certainly an unpleasant addition to outdoor plans, taking steps to avoid them contributes to having a safe and healthy summer.

Jessica Mayer, DO Program Director Suburban Family Medicine ResidencyVice-Chair Family Medicine Department

Suburban Family Medicine at Norristown2705 DeKalb Street, Suite 202Norristown, PA 19401610-275-7240

Dr. Mayer sees patients of all ages and is dedicated to providing compassionate care for the whole person. She is board certified in Family Medicine and director of Suburban Family Medicine Residency program and vice-chair of Family Medicine Department at Suburban Community Hospital.

Dr. Mayer completed her medical education at the Philadelphia College of Osteopathic Medicine (Pennsylvania) in 2008, internship at Crozer-Chester Medical Center (Pennsylvania) in 2009, and Residency at Mercy Suburban Hospital in 2011.

See the article here:
Tips on avoiding mosquitos this summer - morethanthecurve.com

MadameNoire Featured Video

Source: Luke Dray / Getty

With all of the incredible medical advancements made, the HIV virus still escapes the grasp of the worlds top medical researchers and scientists, as the HIV vaccine is still in the works. The medical community managed to find a number of successful COVID-19 vaccine within a year of the viruss existence. Meanwhile, its been forty years since the first reports of people dying from a pneumonia-like virus. That virus was HIV.

Historically, HIV has plagued the Black community at a much higher rate than other races, says the CDC, tragically robbing millions of Black people of full lives, and leaving their loved ones with inconsolable heartbreak. There are a number of reasons for this, including a pervasive lack of access to health care such as preventative drugs and prophylaxis. The CDC also reports that Black people are at a biological disadvantage as theyve been shown to have lower levels of viral suppression against HIV.

Now, with Moderna launching clinical trials for a vaccine, theres new hope of conquering this disease that has taken the lives of 36.3 million people. Heres what we know about the HIV vaccine to date.

Source: BSIP / Getty

To date, there is no approved vaccine for HIV. Its estimated that over 100 HIV vaccines have been tested around the world since the virus was first discovered. However, to date, the only proven method for fighting HIV is antiviral treatments that can reduce the chances of death in individuals who are already infected with the virus. These drugs can be used to prevent the spread of HIV in three ways, says the National Library of Medicine. When taken daily, they can reduce the chances of transmission before exposure as well as after exposure. They can additionally be taken by infected individuals to prolong their lifespan.

Source: gilaxia / Getty

In 2021, Johnson & Johnson conducted what was known as the Imbokodo trials in sub-Saharan Africa. The company enlisted 2,600 women to participate in the trials and receive the vaccine. The vaccine was based on something called mosaic immunogens, says the National Institute of Health, which induce an immune response. Johnson & Johnson had hoped to see at least a fifty percent reduction rate of infection following the vaccine, but only saw a 25 percent reduction and canceled the trials in late 2021.

Source: Ignatiev / Getty

Medical researchers have been fascinated by two individuals who have evidently beat back the virus, without any medical assistance, says Science News. Analysts looked at over 1.5 billion cells from a patient known as EC2 and found zero functional copies of HIV in them. The patient did show nonfunctional copies of HIV, but those do not pose a known threat. These numbers were found after the patient had been infected for a long period of time, so experts believe the chances that the active virus is still simply hiding in the body are low. Another patient had active copies of HIV, but they had landed in a very specific gene that prevented them from spreading. Doctors describe the gene as being Wrapped in the molecular equivalent of razor wire. The immune systems of these two individuals are still being studied and could provide the blueprint for a future vaccine.

Source: Douglas Sacha / Getty

As of 2022, the National Institute of Allergy and Infectious Diseases in collaboration with Moderna has started early trials of three HIV vaccines that are of the same nature as the successful COVID-19 one an mRNA vaccine. The National Institute of Health explains that an mRNA vaccine works by Delivering a piece of genetic material that instructs the body to make a protein fragment of a target pathogen (such as a virus), which the immune system recognizes and remembers, so it can mount a substantial response if later exposed to that pathogen. This is the first study to examine an mRNA vaccine for the prevention of HIV. Participants in the trial will be evaluated at two and six months after injection, at which time samples from their blood and lymph nodes will be assessed. Its important to note that this HIV vaccine cannot cause infection.

RELATED CONTENT:Scientists May Have Successfully Cured HIV In The First Female Patient

See more here:
The HIV Vaccine: What We Know, And What We Don't - MadameNoire

North Korea's first-reported COVID-19 outbreak is the "greatest turmoil" to befall the country since its founding more than 70 years ago, according to its leader Kim Jong Un, as the isolated and impoverished nation scrambles to curb the spread of a highly transmissible virus that risks causing a major humanitarian crisis.North Korea reported 21 more deaths and 174,440 new "fever cases" Friday, according to state media KCNA, though it did not specify how many of the deaths and cases were linked to COVID, likely due to the country's extremely limited testing capacity.The climbing death toll and surging "fever cases" come after North Korea said Thursday it had identified its first ever case of COVID-19 an alarming development for a country with one of the world's most fragile public health systems and a largely unvaccinated population.But given the opaque nature of the regime and the country's isolation from the world a trend that has only exacerbated since the pandemic it is extremely difficult to assess the real situation on the ground.Foreign diplomats and aid workers had fled North Korea en masse in 2021 due to shortages of goods and "unprecedented" restrictions on daily life, making it all the more impossible to obtain information from the country other than through official state media.But North Korean state media reports have been vague, and many important questions remain unanswered, including the country's vaccine coverage and the lockdown's impact on the livelihood of its 25 million people.Here is what we know, and what we don't know about the outbreak:How did the outbreak emerge?North Korean authorities have not announced the cause of the outbreak.North Korea's borders have been tightly sealed since January 2020 to keep the virus at bay, making the so-called "hermit nation" even more isolated from the world. It even declined invitations to send teams to compete at the Tokyo and Beijing Olympics, citing the threat of COVID-19.And as new variants began to emerge, it stepped-up those efforts, cutting off nearly all trade with China the country's biggest trading partner and economic lifeline for the Kim regime with imports from Beijing dropping 99% from September to October 2020.It remains unclear how the virus slipped through the country's tightly-sealed borders.When KCNA reported on the first identification of COVID-19 in the country on Thursday, it did not even specify how many infections had been defected. It simply said samples collected from a group of people experiencing fevers on May 8 had tested positive for the highly contagious omicron variant.By Friday, KCNA was reporting that 18,000 new "fever cases" and six deaths were recorded on Thursday, including one who tested positive for the BA.2 sub-variant of omicron."A fever whose cause couldn't be identified explosively spread nationwide since late April," the newspaper said. "As of now up to 187,800 people are being isolated."On Saturday, KCNA said a total of 524,440 people had reported "fever" symptoms between late April and May 13. Among them, 280,810 people were still being treated in quarantine, while the rest had recovered.Can North Korea cope with a large-scale outbreak?An outbreak of COVID-19 could prove disastrous for North Korea. The country's dilapidated health care infrastructure and lack of testing equipment is unlikely to be up to the task of treating a large number of patients with a highly infectious disease.North Korea's lack of transparency and unwillingness to share information also poses a challenge.North Korea has never formally acknowledged how many died during a devastating famine in the 1990s that experts suggest killed as many as 2 million. Those who fled the country at the time shared horrific stories of death and survival, and a country in chaos."North Korea has such a limited supply of basic medicine that public health officials need to focus on preventative medicine. They would be ill-equipped to deal with any kind of epidemic," Jean Lee, director off the Hyundai Motor-Korea Foundation Center for Korean History at the Washington-based Woodrow Wilson Center, told CNN at the outset of the pandemic.Doctors who have defected in recent years often speak of poor working conditions and shortages of everything from medicine to basic healthcare supplies.Choi Jung-hun, a former physician in North Korea who fled the country in 2011, said when he was helping to combat a measles outbreak in 2006 to 2007, North Korea did not have the resources to operate round-the-clock quarantine and isolation facilities.He recalled that after identifying suspicious cases, manuals for doctors said patients were supposed to be transferred to a hospital or a quarantine facility for monitoring."The problem in North Korea is that manuals are not followed. When there wasn't enough food provided for the people at hospitals and quarantine facilities, people escaped to look for food," Choi said during an interview with CNN in 2020.How is North Korea responding so far?North Korean state media declared the situation a "major national emergency" upon admitting the first officially reported COVID infection.On Thursday, Kim placed all cities into lockdown and ordered "people with fever or abnormal symptoms" into quarantine; he also directed the distribution of medical supplies the government had reportedly stocked in case of a COVID emergency, according to KCNA.Kim later chaired a meeting of the country's powerful politburo, which agreed to implement "maximum" emergency anti-epidemic measures. The measures include isolating work units and pro-actively conducting medical checkups to find and isolate people with "fever and abnormal symptoms," the KCNA reported Friday."Practical measures are being taken to keep the production going at a high rate in the major sectors of the national economy and to stabilize the life of the people to the maximum," KCNA said.According to KCNA, the politburo criticized the country's anti-epidemic sector for "carelessness, laxity, irresponsibility and incompetence," saying it "failed to respond sensitively" to increasing COVID-19 cases across the world, including in neighboring regions.A reporter for Chinese state media CGTN released a rare video from Pyongyang on Friday, recounting his experience on the ground."As far as we know, not many people in Pyongyang have been vaccinated, and the medical and epidemic prevention facilities are in short supply," reporter Zang Qing said in a Weibo post."Because the capital is in lockdown, the food I have at home is only enough for a week. We are still awaiting what policy the government will announce next."At a meeting Saturday, Kim inspected the country's emergency epidemic measures and medical supplies. He also urged North Korean officials to learn from China's "advanced and rich quarantine results and experience they have already achieved in their fight against the malicious infectious disease," according to KCNA.What about North Korea's vaccine coverage?North Korea is not known to have imported any coronavirus vaccines despite being eligible for the global COVID-19 vaccine sharing program, Covax.Assuming most North Koreans are unvaccinated, an outbreak in the country which has limited testing capabilities, inadequate medical infrastructure and which has isolated itself from the outside world could quickly become deadly.Calls are mounting on the country's leadership to provide access to vaccines."There is no evidence to show that North Korea has access to enough vaccines to protect its population from COVID-19. Yet, it has rejected millions of doses of AstraZeneca and Sinovac vaccines offered by the WHO-led Covax program," said Amnesty International's East Asia researcher Boram Jang, in a statement."With the first official news of a COVID-19 outbreak in the country, continuing on this path could cost many lives and would be an unconscionable dereliction of upholding the right to health."In February, Covax reportedly scaled back the number of doses allocated to North Korea because the country failed to arrange for any shipments, according to Reuters.A spokesperson for Gavi, the Vaccine Alliance, said Covax has moved to "needs-based vaccine allocations" and "has currently not committed any volume" for North Korea."In case the country decides to start a COVID-19 immunization program, vaccines could be made available based on criteria of Covax objectives and technical considerations to enable the country to catch up with international immunization targets," the spokesperson said.

North Korea's first-reported COVID-19 outbreak is the "greatest turmoil" to befall the country since its founding more than 70 years ago, according to its leader Kim Jong Un, as the isolated and impoverished nation scrambles to curb the spread of a highly transmissible virus that risks causing a major humanitarian crisis.

North Korea reported 21 more deaths and 174,440 new "fever cases" Friday, according to state media KCNA, though it did not specify how many of the deaths and cases were linked to COVID, likely due to the country's extremely limited testing capacity.

The climbing death toll and surging "fever cases" come after North Korea said Thursday it had identified its first ever case of COVID-19 an alarming development for a country with one of the world's most fragile public health systems and a largely unvaccinated population.

But given the opaque nature of the regime and the country's isolation from the world a trend that has only exacerbated since the pandemic it is extremely difficult to assess the real situation on the ground.

Foreign diplomats and aid workers had fled North Korea en masse in 2021 due to shortages of goods and "unprecedented" restrictions on daily life, making it all the more impossible to obtain information from the country other than through official state media.

But North Korean state media reports have been vague, and many important questions remain unanswered, including the country's vaccine coverage and the lockdown's impact on the livelihood of its 25 million people.

Here is what we know, and what we don't know about the outbreak:

North Korean authorities have not announced the cause of the outbreak.

North Korea's borders have been tightly sealed since January 2020 to keep the virus at bay, making the so-called "hermit nation" even more isolated from the world. It even declined invitations to send teams to compete at the Tokyo and Beijing Olympics, citing the threat of COVID-19.

And as new variants began to emerge, it stepped-up those efforts, cutting off nearly all trade with China the country's biggest trading partner and economic lifeline for the Kim regime with imports from Beijing dropping 99% from September to October 2020.

It remains unclear how the virus slipped through the country's tightly-sealed borders.

When KCNA reported on the first identification of COVID-19 in the country on Thursday, it did not even specify how many infections had been defected. It simply said samples collected from a group of people experiencing fevers on May 8 had tested positive for the highly contagious omicron variant.

By Friday, KCNA was reporting that 18,000 new "fever cases" and six deaths were recorded on Thursday, including one who tested positive for the BA.2 sub-variant of omicron.

"A fever whose cause couldn't be identified explosively spread nationwide since late April," the newspaper said. "As of now up to 187,800 people are being isolated."

On Saturday, KCNA said a total of 524,440 people had reported "fever" symptoms between late April and May 13. Among them, 280,810 people were still being treated in quarantine, while the rest had recovered.

An outbreak of COVID-19 could prove disastrous for North Korea. The country's dilapidated health care infrastructure and lack of testing equipment is unlikely to be up to the task of treating a large number of patients with a highly infectious disease.

North Korea's lack of transparency and unwillingness to share information also poses a challenge.

North Korea has never formally acknowledged how many died during a devastating famine in the 1990s that experts suggest killed as many as 2 million. Those who fled the country at the time shared horrific stories of death and survival, and a country in chaos.

"North Korea has such a limited supply of basic medicine that public health officials need to focus on preventative medicine. They would be ill-equipped to deal with any kind of epidemic," Jean Lee, director off the Hyundai Motor-Korea Foundation Center for Korean History at the Washington-based Woodrow Wilson Center, told CNN at the outset of the pandemic.

Doctors who have defected in recent years often speak of poor working conditions and shortages of everything from medicine to basic healthcare supplies.

Choi Jung-hun, a former physician in North Korea who fled the country in 2011, said when he was helping to combat a measles outbreak in 2006 to 2007, North Korea did not have the resources to operate round-the-clock quarantine and isolation facilities.

He recalled that after identifying suspicious cases, manuals for doctors said patients were supposed to be transferred to a hospital or a quarantine facility for monitoring.

"The problem in North Korea is that manuals are not followed. When there wasn't enough food provided for the people at hospitals and quarantine facilities, people escaped to look for food," Choi said during an interview with CNN in 2020.

North Korean state media declared the situation a "major national emergency" upon admitting the first officially reported COVID infection.

On Thursday, Kim placed all cities into lockdown and ordered "people with fever or abnormal symptoms" into quarantine; he also directed the distribution of medical supplies the government had reportedly stocked in case of a COVID emergency, according to KCNA.

Kim later chaired a meeting of the country's powerful politburo, which agreed to implement "maximum" emergency anti-epidemic measures. The measures include isolating work units and pro-actively conducting medical checkups to find and isolate people with "fever and abnormal symptoms," the KCNA reported Friday.

"Practical measures are being taken to keep the production going at a high rate in the major sectors of the national economy and to stabilize the life of the people to the maximum," KCNA said.

According to KCNA, the politburo criticized the country's anti-epidemic sector for "carelessness, laxity, irresponsibility and incompetence," saying it "failed to respond sensitively" to increasing COVID-19 cases across the world, including in neighboring regions.

A reporter for Chinese state media CGTN released a rare video from Pyongyang on Friday, recounting his experience on the ground.

"As far as we know, not many people in Pyongyang have been vaccinated, and the medical and epidemic prevention facilities are in short supply," reporter Zang Qing said in a Weibo post.

"Because the capital is in lockdown, the food I have at home is only enough for a week. We are still awaiting what policy the government will announce next."

At a meeting Saturday, Kim inspected the country's emergency epidemic measures and medical supplies. He also urged North Korean officials to learn from China's "advanced and rich quarantine results and experience they have already achieved in their fight against the malicious infectious disease," according to KCNA.

North Korea is not known to have imported any coronavirus vaccines despite being eligible for the global COVID-19 vaccine sharing program, Covax.

Assuming most North Koreans are unvaccinated, an outbreak in the country which has limited testing capabilities, inadequate medical infrastructure and which has isolated itself from the outside world could quickly become deadly.

Calls are mounting on the country's leadership to provide access to vaccines.

"There is no evidence to show that North Korea has access to enough vaccines to protect its population from COVID-19. Yet, it has rejected millions of doses of AstraZeneca and Sinovac vaccines offered by the WHO-led Covax program," said Amnesty International's East Asia researcher Boram Jang, in a statement.

"With the first official news of a COVID-19 outbreak in the country, continuing on this path could cost many lives and would be an unconscionable dereliction of upholding the right to health."

In February, Covax reportedly scaled back the number of doses allocated to North Korea because the country failed to arrange for any shipments, according to Reuters.

A spokesperson for Gavi, the Vaccine Alliance, said Covax has moved to "needs-based vaccine allocations" and "has currently not committed any volume" for North Korea.

"In case the country decides to start a COVID-19 immunization program, vaccines could be made available based on criteria of Covax objectives and technical considerations to enable the country to catch up with international immunization targets," the spokesperson said.

Read more from the original source:
What we know (and don't know) about North Korea's COVID-19 outbreak - WCVB Boston

Experts across the UAE have warned of the health impacts from the dusty conditions caused by sandstorms which have blanketed large parts of the country this week.

This week, forecasters issued a countrywide alert of hazardous weather due to sandstorm-related dust conditions.

For all the latest headlines follow our Google News channel online or via the app.

In recent days, the dusty weather has descended over almost all of the UAE.

As winds blow dust and sand into the atmosphere - affecting not only visibility - it also acerbates existing health conditions among residents, say doctors.

Dr Rakesh Kumar Gupta, deputy medical director and specialist pulmonologist of Lifecare Hospital, Musaffah, told Al Arabiya English: In this dusty weather, a higher number of patients seek medical attention for respiratory issues.

Exposure to sandstorms can cause health problems in people in the high-risk category like patients with pre-existing respiratory conditions, pregnant women, children, the elderly, and those who work outdoors.

While the larger dust particles can irritate the eyes, nose and throat, the finer particles can irritate the lungs and lead to allergic reactions.

Sandstorm exposure may worsen conditions like chronic obstructive pulmonary disease, asthma, and cardiovascular diseases. It may also trigger an acute attack of asthma in previously stable asthmatics, so these patients must take extra care.

The doctor said is necessary to take adequate precautions during a sandstorm.

Avoid going outside, especially when there is low visibility and high winds. Carry water with you to stay hydrated. Keep your mouth and nose covered with a mask or respirator. Wear protective eyewear and rinse your eyes with water if your eyes are irritated.

People with bad allergies can continue taking prescribed medications like antihistamines. If you experience symptoms like coughing, wheezing, breathing difficulty, chest pain or chest discomfort, seek medical help immediately.

Dr Muhammed Aslam, a specialist in pulmonology at the International Modern Hospital in Dubai, told Al Arabiya English that sandstorms can be detrimental to peoples health.

Nowadays we are seeing a lot of sandstorm episodes in the country; this is harmful to our health.

It affects our lungs, our respiratory system, our nose, our eyes. Also, those who already have allergies such as asthma are more prone to develop more systems such as runny nose, sneezing, throat discomfort, coughing and difficulty breathing, wheezing, and chest tightness.

It happens because of dust particles, while other virus particles can also be spread due to the sandstorm.

So the preventative measures is to stay indoors dont go outside if the sandstorm is heavy and watch the local weather forecast so you can monitor your activities.

Also, use air conditioning so that outside air will not come inside, and use allergy medicine if you are already allergies. You may need to up the dosage of your medicines as well but consult your doctor before doing so.

Ahmed El Mansoury, a consultant in pulmonology at NMC Royal Hospital in Sharjah, also said sandstorms can cause an increase in respiratory problems such as asthma and some infectious diseases such as pneumonia due to circulated dust particles, causing wheezing and coughing,

The best precaution is to stay at home; if you have to go outside then wear a mask or some protective device like you see with COVID-19 such as protection of eyes and hand washing and normal other precautions for respiratory illnesses.

Forecasters at the National Center of Meteorology said much of the same weather is expected over the course of the next few days, with a high likelihood of dust and sand affecting visibility up until at least Sunday.

A sandstorm has also engulfed Saudi Arabias capital and other regions of the Kingdom this week, hampering visibility and slowing road traffic.

Read more:

Sandstorm blankets Saudi Arabias capital Riyadh

Iraq sandstorm sends more than 1,000 to hospital

Originally posted here:
Experts warn of health effects from dusty conditions as sandstorm blankets UAE - Al Arabiya English

Between 25% and 30% of older adults in theUnited StatesandEuropetake statins to treat or prevent atherosclerosis cardiovascular disease (ACVD) the buildup of cholesterol plaque in artery walls that stops blood flow.

Although effective in decreasing ACVD-related deaths, their effects differ between people. While pharmacological and genetic factors are known to contribute to statin response, personalized approaches remain limited.

Recentstudieshave suggested a link between the gut microbiome and statin use and the gut microbiome andACVD risk. Otherstudieshave found that gut bacteria metabolize statins into secondary compounds.

Knowing whether and how gut microbiome composition affects peoples response to statins could help researchers and clinicians personalize statin-based treatments.

In a recent study, researchers investigated whether and how the gut microbiome composition affects a persons response to statins and metabolic health.

They found that differences in gut microbiome composition influenced peoples response to statins as well as metabolic health parameters, including insulin resistance and blood glucose levels.

The authors present very compelling work linking the microbiome with the efficacy and toxicity of statin medications,Dr. Sony Tuteja, Research Assistant Professor of Medicine at the University of Pennsylvania, not involved in the study, toldMedical News Today.

This adds to the already large amount of work pointing to the microbiome in explaining the variation in drug response that cannot be explained by host genetics, she added.

The new study was published in the journalMed.

For the study, the researchers built statistical models with data from 1,848 participants from the Arivale cohort study.

Data included microbiome composition from stool samples and plasma metabolite levels from blood samples. The researchers also made use of genomics and demographics data.

They also used data from 991 individuals from the European MetaCardis cohort to validate their model.

Statins work byinhibitinga rate-limiting enzyme involved in cholesterol synthesis, known as HMG-CoA reductase.

The researchers first sought to see whether HMG levels could be linked with statin use. They found that HMG levels positively correlate with statin use and inversely correlate with LDL cholesterol.

This, they wrote, means that HMG levels may indicate the extent to which statins inhibit their target enzyme. So, they used levels of HMG in the blood to represent statin use.

In their analysis, the researchers found that people with more diverse microbiomes exhibited lower HMG levels, indicating a decreased statin response.

Further analysis showed that individuals with a Bacteroides-dominated gut microbiome had the strongest on-target effects including high plasma HMG and low LDL cholesterol levels.

However, they also had the greatest metabolic disruption as measured by glucose levels and insulin resistance.

Meanwhile, people with Ruminococcaceae-dominated gut microbiomes demonstrated a clear LDL-lowering response without metabolic disruption.

The researchers suggest that this microbiome composition type may thus benefit from statin therapy without metabolic complications.

To explain the results, the researchers noted that Rum. bacteria is enriched in bacterial species that may serve as a buffer against off-target metabolic effects.

They also note that bacterial species in Rum. microbiomes metabolize statins and other prescription drugs at a lower rate than other microbiome compositions, which may explain their resistance to metabolic issues from statin use.

By contrast, Bacteriodes bacteria metabolize statins, potentially explaining the metabolic effects of statin use in Bacteriodes-dominated microbiomes.

Adding to this,Dr. Sean Gibbons, Washington Research Foundation Distinguished Investigator and Assistant Professor at the Institute for Systems Biology, one of the studys authors, told MNT:

We also saw an association between statin responses and mucus degrading genes in the metagenomes i.e. greater mucus degradation capacity was associated with more intense statin responses, which is in line with arecent preprint.

Finally, there is evidence that bacterial bile acid metabolism influences cholesterol levels in the body, with a recentstudyshowing how certain secondary bile acids produced by microbes were associated with lowering LDL cholesterol in blood, he added.

Dr. Tuteja also noted: Microbially derived metabolites, such as bile acids, may be competing with host drug uptake transporters which will limit the amount of statin medication reaching the liver.

Statins alter the microbiome composition and, in particular, those bacteria with the ability to metabolize bile acids, altering the bile acid pool, which impacts cholesterol biosynthesis, she continued.

Dr. Oluf Pedersen, professor of human metabolism at the University of Copenhagen, Denmark, added that the underlying molecular mechanisms remain unknown.

However, he noted that interindividual variation in statin response might arise as different microbiome compositions influence glucose and cholesterol synthesis by the liver differently.

The researchers concluded that microbiome composition influences peoples response to statins independently of genetic markers. They add that further research monitoring the gut microbiome may help inform precision statin treatment.

When asked about the studys limitations, Dr. Tuteja explained:

The major limitation is the cross-sectional design. Prospective, interventional studies will be required to determine the directionality of the effect.

The authors present data from two descriptive observational studies and cannot tell if there are any causal relationships. To address this, long-term intervention studies are needed, [including detailed analysis of the gut microbiome] before and after a period of statin intake [alongside] careful measurements of carbohydrate and lipid metabolism, added Dr. Pedersen.

Read the original here:
Statin therapy: Does the gut microbiome affect outcomes? - Medical News Today

MarketQuest.biz latest record at the Global Nanomaterials in Personalized Medicine Market is predicted to experience excessive growth from 2022 to 2028. The report is an in-depth analysis of a wealthy supply of main factors liable for developing the global Nanomaterials in Personalized Medicine market. The study has captured several factors that have had or are having a substantial influence on the industry. The data factors like the drivers, flow patterns, openings, restrictions, and information are gathered through actual sources for plans for the Nanomaterials in Personalized Medicine market.

The Report Consists of:

DOWNLOAD FREE SAMPLE REPORT: https://www.marketquest.biz/sample-request/125574

The report focuses on the studies of earlier and contemporary market attributes, which form a basis for evaluating the possibilities of the industry. The study assists in the identification of new marketing possibilities & provides a comprehensive view of the current global Nanomaterials in Personalized Medicine market. The record offers company profile of the key vendors operating in the Nanomaterials in Personalized Medicine industry and comparative analysis based on their business product offering, overviews, segment market share, business strategies, regional presence, innovations, joint venture, M&A, SWOT analysis, recent developments, collaborations, partnerships, and key financial information.

The worldwide Nanomaterials in Personalized Medicine market research is divided into categories that include

The global Nanomaterials in Personalized Medicine market study is classified into applications that cover

Some of the most promising vendors include:

ACCESS FULL REPORT: https://www.marketquest.biz/report/125574/global-nanomaterials-in-personalized-medicine-market-2022-by-company-regions-type-and-application-forecast-to-2028

The regional segments of the market include:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketquest.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketquest.biz

View original post here:
Global Nanomaterials in Personalized Medicine Market (Impact Of COVID-19) Growth, Overview With Detailed Analysis 2022-2028 Queen Anne and Mangolia...

ReportLinker

In-depth Analysis and Data-driven Insights on the Vendor Landscape, Competitive Analysis, and Critical Market Strategies are Included in this Global Biomarkers Market Report. Biomarkers are increasingly useful tools to predict prognosis and response to therapy in cancer patients.

New York, May 02, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Biomarkers Market - Global Outlook & Forecast 2022-2027" - https://www.reportlinker.com/p06272725/?utm_source=GNW Furthermore, it allows to improve understanding of mechanisms of action and resistance to treatment.

The global biomarkers market is expected to grow at a CAGR of 11.44%.

KEY HIGHLIGHTS

Increased Adoption of Biomarkers in Personalized Medicine is driving the global biomarkers market growth. As many healthcare settings have gained interest in personalized/precision medicine, many vendors have increased the studies focussing on identifying biomarkers to provide healthcare system solutions to them. Increasing focus on digital biomarkers will also drive the global Currently, several digital biomarkers are being tested for feasibility and reliability in Parkinsons and Alzheimers disease and clinical outcome assessments. Increasing discovery of epigenetic biomarkers for oncology is also driving the biomarker technologies market. There are more emerging companies increasing their research & development focus on discovering more epigenetics to diagnose various types of cancers. Technological Advancements in Biomarker Discovery are also positively impacting the biomarkers diagnostics industry. For instance, a recent development in portable biosensors allows rapid, accurate, and on-site detection of biomarkers, which helps prevent disease spread by controlling sources.

GROWTH ENABLERS

Increase In Number of Pipeline Biomarkers Rising Adoption of Biomarkers In Disease Diagnostics Technological Advancements in Biomarker Discovery

GLOBAL BIOMARKERS MARKET SEGMENTATION Oncology dominated the indication segment because biomarkers are being largely used for cancer research and diagnostics due to its high prevalence worldwide. Biomarkers in the field of oncology has revolutionized the diagnostics and treatment pathways.

Diagnostics dominated the application segment. However, the application of biomarkers in drug discovery & development is expected to grow significantly during the forecast period because biomarkers studies is expected to become an integral part of the drug development process with the aim of developing more effective drugs at a lower cost

Diagnostic biomarker dominated the type of segment as diagnostic biomarker studies have entered a new era where it holds promise for early diagnosis and effective treatment of many diseases.

Segmentation by Indication Oncology Cardiology Neurology Immunology Others

Segmentation by Application Diagnostics Drug Discovery & Development Personalized Medicine (PM) Others

Segmentation by Type Diagnostic Biomarker Monitoring Biomarker Prognostic Biomarker Susceptibility Biomarker Other Biomarker

VENDOR ANALYSIS Multiple companies partnering and investing in biomarkers research and development will help the companies to innovate new drugs and reduce the economic burden.

Key Vendors

Abbott company BioMerieux Biohit OYJ CENTOGENE Creative Diagnostics F. Hoffmann-La Roche company Fujirebio General Electric (GE) company TAmiRNA

Other Prominent Vendors

Accure Therapeutics Agilent Almac Group Applied Research Using OMIC Sciences (AROMICS) Bio-Rad Laboratories BioVision Caris Life Sciences Denovo Biopharma Dreamgenics Eisai Epigenomics Immunovia Insilico Medicine Lexogen Monument Tx Oryzon Genomics Plexision Rules-Based Medicine Siemens Healthineers Second Genome Therapeutics Thermo Fisher Scientific Ymir Genomics

GEOGRAPHICAL ANALYSIS North America dominated the geography because biomarkers have been in use highly for diagnostic purposes, drug discovery & development, and precision medicine. The increase in R&D expenditures and fundings for biomarker-driven drug discovery & development and precision medicine is one of the major driving factors in all the regions.

APAC is anticipated to exhibit the highest CAGR of 13.96% during the forecast period. Increasing developments and incorporation of advanced technologies to enhance the biomarker-based testing and increasing demand for biomarkers in drug development and personalized medicine are one of the primary factors in the region.

Segmentation by Geography

North America o US o Canada

Europe o Germany o France o UK o Italy o Spain

APAC o Japan o China o India o South Korea o Australia

Latin America o Brazil o Mexico o Argentina

Middle East & Africa o Turkey o South Africa o Saudi Arabia

THE REPORT INCLUDES: 1. The analysis of the global Biomarkers market size and growth rate for the forecast period 2022-2027. 2. It offers comprehensive insights into current industry trends, trend forecast, and growth drivers about the global Biomarkers market. 3. The report provides the latest analysis of market share, growth drivers, challenges, and investment opportunities. 4. It offers a complete overview of market segments and the regional outlook of the Biomarkers market.Read the full report: https://www.reportlinker.com/p06272725/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Go here to see the original:
The global biomarkers market is expected to grow at a CAGR of 11.44%. - Yahoo Finance